Kelly Chien
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kelly Chien as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06597734 · A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative NeoplasmM.D. Anderson Cancer Center · withdrawn · Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms, IDH1-mutated Higher-Risk Myelodysplastic Syndromes · principal investigator
- Ph2NCT06566742 · A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.M.D. Anderson Cancer Center · recruiting · Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:09 UTC. The ranking covers the 200 most relevant of 61 PubMed records, and a shared surname and initials can bring in a namesake. All 61 on PubMed
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.Lancet Haematol · 2023236 citationsRCR 20.8
- Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.J Clin Oncol · 2024179 citationsRCR 23.4
- Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics.J Proteomics · 201390 citationsRCR 3.0
- Treatment of low back pain by acupressure and physical therapy: randomised controlled trial.BMJ · 200688 citationsRCR 3.7
- 87 citationsRCR 2.6
- Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting.Mol Ther · 202387 citationsRCR 7.1
- 83 citationsRCR 5.5
- A pilot study of anisometropic amblyopia improved in adults and children by perceptual learning: an alternative treatment to patching.Ophthalmic Physiol Opt · 200858 citationsRCR 2.2
- Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.Br J Haematol · 202156 citationsRCR 2.7
- 47 citationsRCR 10.6